Skip to content

CytomX Therapeutics, Inc.

CTMX

CIK 0001501989

← back to feed
Revenue (TTM)
$85.8M
−44.8% YoY Q1 Apr 2026
Net Income (TTM)
−$9.11M
−154.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
—
Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-16.4%
Q1 Apr 2026
Net Margin
-10.6%
Q1 Apr 2026
Free Cash Flow (TTM)
−$63.57M
Q1 Apr 2026
Cash
$28.83M
Q1 Apr 2026
Total Debt
$2.99M
Q1 Apr 2026
Shares Outstanding
217.7M sh
Q1 Apr 2026

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings